ZYBERNO
Stock Report
Updated Sep 1, 2026

JASPER THERAPEUTICS, INC. (JSPR)

Healthcare • NASDAQ

$0.70

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
JASPER THERAPEUTICS, INC. (JSPR) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-618.9%)
Debt-to-Equity (Solvency Risk):GOOD (0.38x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-921.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

JASPER THERAPEUTICS, INC. (JSPR) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.70
Market Cap:$20.22M

Valuation Multiples (2)

P/B Ratio:14.31x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$13.45M

Price Action & Momentum (1)

% of 52-Week High:23.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-100.7%
Reinvestment Rate:2.6%
Fundamental Growth Rate (g):-23.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$517.66
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:93.9%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.47x
Quick Ratio:1.47x
Cash Ratio:0.93x

Leverage Analysis (3)

Debt To Equity Ttm:0.38x
Debt-to-Equity Ratio:0.38x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:3,726,000.00
Cash And Cash Equivalents:7,314,000.00
Long Term Debt:$270.00K
Net Debt:-$6.77M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$41.64M

Profitability Breakdown (2)

$0.00-$55.16M

Bottom Line Performance (3)

-$31.77M
Income Before Tax:$0.00
Ebitda Ttm:-33,624,000.00

Operating Expenses (5)

Operating Expenses:55,164,000.00
R And D Expense:36,700,000.00
Sga Expense:18,464,000.00
Income Tax Expense:$95.08K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$11.80M
Current Assets:$11.57M
Ppe Net:4,274,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:10,389,000.00
Current Liabilities:7,845,000.00
Long Term Debt:$270.00K
Short Term Debt:$270.00K

Equity & Capital (3)

Equity:$1.41M
Retained Earnings:-$320.60M
Common Stock:492,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:2,778,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:423,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$68.87M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:-$340.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,500,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:21,540,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.09
-$4.09
Earnings Per Share Ttm:-$1.11

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.69

Book Value & Capital (2)

Book Value Per Share:$0.05
Cash Per Share:0.25

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:24.35
Cash Conversion Cycle:-2,022.35
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.6%
Fundamental Growth Rate (g):-23.5%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:JSPR
Company Name:JASPER THERAPEUTICS, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:28.70M
Shares Outstanding Basic:28.70M
Shares Outstanding Diluted:28.70M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:34:21 UTC
Data Timestamp:2026-08-21T12:35:31.924696
Scroll to Top